Traded Feb 5 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Traded Jan 5, 2026 · Filed Jan 8, 2026
United Therapeutics's PRESIDENT AND COO sold $181K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$180,737
Shares × reported transaction price
68 days after results of Oct 29, 2025, 51 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.8% | +0.4% | −4.2% |
| 30 days | −3.6% | +0.6% | −4.3% |
| 90 days | +18.5% | −2.0% | +20.5% |
| 180 days | +14.8% | +8.4% | +6.4% |
Past results only. Not a forecast.
Traded Feb 5 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Paul A Mahon (EVP & GENERAL COUNSEL) sold ~$229K of United Therapeutics
Scheduled in advancePaul A Mahon (EVP & GENERAL COUNSEL) sold ~$1.14M of United Therapeutics
Scheduled in advance